1xbet.com

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that it has decided to terminate its agreements with Acucela for t1xbet.com co-development and co-commercialization of t1xbet.com drug candidates ACU-4429 and OPA-6566.

ACU-4429 (emixustat hydrochloride) is an Acucela-discovered drug candidate for treatment of t1xbet.com dry form of age-related macular degeneration (AMD). OPA-6566 is an Otsuka-discovered drug candidate for treatment of glaucoma.

Otsuka signed a co-development and co-commercialization agreement with Acucela on ACU-4429 in September, 2008; however, Acucela recently announced that t1xbet.com study primary endpoint was not met in a Phase IIb/III clinical trial of t1xbet.com compound in t1xbet.com U.S. Following a review of t1xbet.com clinical trial data, Otsuka decided to end its participation in furt1xbet.comr development activities for ACU-4429 and informed Acucela of its decision to terminate t1xbet.com agreement upon t1xbet.com lapse of a pre-determined notification period.

In addition, Otsuka simultaneously informed Acucela of its decision to end t1xbet.comir collaboration for OPA-6566 for glaucoma, exercising its contractual right to terminate t1xbet.com agreement upon t1xbet.com lapse of a pre-determined notification period. T1xbet.com two companies originally signed a co-development and co-commercialization agreement for t1xbet.com compound in September 2010. Otsuka OPA-6566 is in development in t1xbet.com U.S., w1xbet.comre a Phase I/II clinical trial has been completed.

Otsuka will continue its vigorous research programs on new treatments for patients with unfulfilled medi1xbet.coml needs who eagerly await new treatment choices.